Pricing Log in Create free account
Saturday 17 October 2026 Export DBVT’s income statement to Excel — free account

DBV Technologies S.A.

DBVT Healthcare Biotechnology

DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024. In the quarter to June 2026, revenue fell 53.3%, EPS grew 61.3% and free cash flow fell 56.2%, each against the same quarter a year earlier.

9.05 0.06 −0.66%
Market cap
$572.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
1.33
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 15.51
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 1 1 — — — — — 1 — — —
Insider Ownership 37.50%

Capital & Financial Ratios $m

Market Cap 572.56
Revenue 4.94
Net Income (175.95)
Free Cash Flow (170.61)
Net Debt (174.90)
Current Ratio 3.72 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 158.97 (above 10: high)
P/B ratio 4.89
Past 5Y EPS Growth —
This Y EPS Growth 28.64% (at or above 15%: strong)
Next Y EPS Growth 43.06% (at or above 15%: strong)
Next Y revenue growth —
Next 5Y EPS Growth 56.91% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 124×, against a ten-year median of −5.1×; over the ten years it ranged from −34.7× in 2023 to 274× in 2026.
P/S against its own 10 years 90.65%
10-year low 10-year high
P/B against its own 10 years 83.45%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 141 32 194 175
Receivables — — — —
Inventory — — — —
Other 18 12 19 27
159 44 213 202
2023 2024 2025 Q'26
Payables 23 22 41 39
ST’ Debt — — — —
Other 13 8 16 14
37 31 58 54

Compound Annual Growth %

10y 5y 3y
Sales (1.93%) (12.95%) 5.18%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (7.23%) (3.86%) (4.61%)

Revenue $m

Mar Jun Sep Dec Year
’26 1 1 — — —
’25 1 2 3 1 6
’24 1 1 1 1 4
’23 2 2 2 9 16
’22 3 2 2 (1) 5
’21 3 (1) 1 3 6
’20 5 4 4 (1) 11
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (49) (53) — — —
’25 (20) (34) (32) (35) (121)
’24 (35) (35) (22) (12) (104)
’23 (21) (26) (20) (14) (80)
’22 (1) (10) (20) (24) (56)
’21 (36) (30) (23) (19) (108)
’20 (50) (38) (45) (34) (166)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (49) (53) — — —
’25 (20) (34) (33) (36) (122)
’24 (36) (36) (23) (12) (107)
’23 (21) (26) (20) (14) (80)
’22 (2) (10) (20) (24) (56)
’21 (36) (30) (23) (19) (109)
’20 (51) (38) (45) (34) (168)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.56) (0.60) — — —
’25 (1.32) (1.55) (1.20) (1.15) (5.25)
’24 (1.40) (1.70) (1.58) (1.10) (5.85)
’23 (1.10) (1.30) (0.90) (0.60) (3.80)
’22 (1.50) (1.80) (0.90) (2.30) (6.20)
’21 (2.70) (2.80) (2.20) (1.30) (8.90)
’20 (3.95) (1.81) (2.82) (3.59) (14.80)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 45.10 41.16 7.20 11.54 2.70 2.70 2.16 1.30 0.44 3.15

Analyst estimates 2026–2028

Powerpack
High 75.96 101.14 53.96 22.46 26.98 14.76 6.86 4.74 4.50 26.19
People
People Employees 164 244 315 311 142 92 85 104 109 125
Revenue/emp, $m 0.06 0.06 0.05 0.05 0.08 0.06 0.06 0.15 0.04 0.05
Income, $m
Income, $m Revenue 10 13 17 15 11 6 5 16 4 6
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (127) (167) (196) (171) (160) (98) (96) (73) (114) (146)
EBT margin, % (1,260.79) (1,240.18) (1,142.33) (1,165.36) (1,415.09) (1,720.20) (1,986.04) (462.35) (2,743.03) (2,598.58)
Net income (127) (167) (196) (172) (160) (98) (96) — (114) (147)
Depreciation 1 3 3 3 10 8 13 (14) (1) 3
Per share, $
Per share, $ Revenue 2.06 2.72 2.97 1.99 1.04 0.52 0.31 0.83 0.21 0.20
Earnings (25.90) (33.70) (33.90) (23.30) (14.80) (8.90) (6.20) (3.80) (5.85) (5.25)
Cash flow (13.47) (26.10) (27.89) (20.04) (15.31) (9.86) (3.60) (4.19) (5.39) (4.34)
Capex (1.86) (1.72) (0.97) (0.76) (0.26) (0.03) (0.05) (0.04) (0.12) (0.02)
Free cash flow (15.33) (27.82) (28.86) (20.80) (15.56) (9.88) (3.64) (4.22) (5.51) (4.36)
Book value 54.95 29.66 24.76 26.10 18.99 9.04 12.56 7.37 1.41 6.05
Shares, m 5 5 6 7 11 11 15 19 19 28
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 0.00 5.03 6.16 9.59 2.29 14.44 94.95
P/B 0.00 0.00 0.00 0.00 0.28 0.35 0.24 0.26 2.19 3.17
EV/Sales 0.00 0.00 0.00 0.00 (12.34) (7.35) (33.56) (6.69) 6.66 60.52
EV/FCF 0.00 0.49 0.32 0.39 0.83 0.39 2.88 1.31 (0.26) (2.80)
Cash, $m
Cash, $m Operating cash flow (66) (129) (161) (148) (166) (108) (56) (80) (104) (121)
Capex (9) (9) (6) (6) (3) 0 (1) (1) (2) (1)
Free cash flow (75) (138) (167) (154) (168) (109) (56) (80) (107) (122)
Balance, $m
Balance, $m Working capital 269 137 120 151 155 83 194 122 13 155
Total debt 4 2 2 1 1 7 1 — — —
Net debt (279) (154) (143) (192) (196) (77) (209) (141) (32) (194)
Shareholders’ equity 269 147 143 193 205 99 194 140 27 169
Returns, %
Returns, % ROA (36.25) (64.32) (97.14) (72.49) (58.66) (46.69) (48.96) (33.87) (91.63) (98.17)
ROIC 0.00 0.00 0.00 (14,425.02) (1,025.38) (280.50) 0.00 0.00 0.00 0.00
ROE (40.47) (80.34) (135.22) (102.26) (80.04) (64.19) (65.55) (43.47) (135.96) (149.83)
Negative figures in brackets.
value withheld pending a data check

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

DBV Technologies S.A. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OLMA Olema Pharmaceuticals, Inc. $601.1M — (loss-making) — — n/m −54.33% (below 0%: shrinking) 0.00% 0.00% Compare
CRMD CorMedix Inc $581.5M 3.0× 16.5× +156.52% (above 0%: growing) +13.79% (above 0%: growing) +185.90% (above 0%: growing) 75.66% 42.10% Compare
SLN Silence Therapeutics PLC Sponsored ADR $581.1M — (loss-making) — (loss-making) +197.18% (above 0%: growing) n/m +106.95% (above 0%: growing) 97.39% 0.00% Compare
SGMT Sagimet Biosciences Inc. $574.7M — (loss-making) — (loss-making) — n/m −21.95% (below 0%: shrinking) 100.00% 0.00% Compare
DBVT DBV Technologies S.A. $572.6M — (loss-making) — −53.33% (below 0%: shrinking) n/m −56.15% (below 0%: shrinking) 100.00% (7,228.57%)
VALN Valneva SE Sponsored ADR $560.4M 59.7× 19.4× −17.29% (below 0%: shrinking) n/m −56.05% (below 0%: shrinking) 15.29% (76.67%) Compare
STTK Shattuck Labs, Inc. $555.0M — (loss-making) — (loss-making) −10.31% (below 0%: shrinking) n/m +1.01% (above 0%: growing) 100.00% 0.00% Compare
VECT VectivBio Holding AG $545.5M — (loss-making) — (loss-making) — n/m — 91.93% 0.00% Compare
PBYI Puma Biotechnology, Inc. $543.0M 18.2× 24.2× +7.75% (above 0%: growing) +33.33% (above 0%: growing) −88.45% (below 0%: shrinking) 77.92% 13.42% Compare
Median of peers $567.5M 18.2× 19.4× +7.75% — −21.95% 84.93% 0.00%

All 614 Biotechnology stocks →

DBV Technologies S.A. (DBVT) key facts

  • Strength: DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024.
  • DBV Technologies S.A. (DBVT) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, DBVT traded at $9.05, a market capitalization of $572.6 million.
  • Return on equity was −149.8% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.33 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

DBV Technologies S.A. (DBVT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/DBVT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com